Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Abstract 4685: Characterization of variants of uncertain significance (VUS) in breast and ovarian cancer predisposition genes
Schröeder, Andreas , Hallberg, Emily, Lipton, Gary, Iversen, Edwin S. , Lindor, Noralane M. , Couch, Fergus J. , Shimelis, Hermela , Hu, Chunling

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4685-4685

10.1158/1538-7445.am2015-4685 Get It

Abstract Panel-based germline genetic testing of established breast and ovarian cancer predisposition genes is widely used in high-risk clinics to inform on risks of breast and ovarian cancer. While most protein truncating mutations identified in predisposition genes are associated with moderate to high risks of these cancers, variants of uncertain significance (VUS), in the form of missense and intronic variants, have an undefined relevance to cancer. Many hundreds of VUS in BRCA1 and BRCA2 identified by clinical genetic testing over the last 20 years still have uncertain clinical relevance. In addition, VUS in other known predisposition genes are being identified by current panel-testing in up to 10% of individuals without BRCA1 or BRCA2 mutations. These VUS cause problems in cancer risk estimation and clinical management of patients undergoing clinical genetic testing. In an effort to evaluate the clinical significance of VUS in cancer predisposition genes we have developed functional assays that characterize the impact of the variants on the functions of the proteins encoded by the predisposition genes. In particular, a homology directed repair reporter assay providing a quantitative measure of homologous recombination repair of DNA double strand breaks has been developed for characterization of VUS in homologous recombination associated genes. When applied to 13 known pathogenic and 30 known neutral variants from the DNA binding domain of BRCA2, this assay exhibits 100% specificity and 100% sensitivity. Based on these results a model estimating the probability of pathogenicity of each BRCA2 VUS was developed. The HDR assay and probability model has now been applied to 230 BRCA2 VUS identified through genetic testing. Here we identify 80 BRCA2 variants that are deficient in HDR activity. We further combined these results with prior probabilities of pathogenicity derived from the sequence based Align GVGD in silico prediction model to estimate the posterior probability of pathogenicity for each VUS. Our results suggest that in the absence of family based segregation information, results from the HDR functional assay and in silico prediction models can be used to predict the pathogenicity of BRCA2 VUS. The assay has also been used to characterize VUS in the PALB2 and RAD51C predisposition genes, leading to identification of a subset of missense variants that are deficient in HDR repair activity and may be associated with increased risk of breast and ovarian cancer. These results will prove useful for improved risk assessment of carriers of these BRCA2, PALB2 and RAD51C variants and their family members and for validation of other approaches to mutation classification. Citation Format: Fergus J. Couch, Hermela Shimelis, Andreas Schroeder, Chunling Hu, Emily Hallberg, Gary Lipton, Edwin Iversen, Noralane M. Lindor. Characterization of variants of uncertain significance (VUS) in breast and ovarian cancer predisposition genes. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4685. doi:10.1158/1538-7445.AM2015-4685
Abstract 4684: Assessment of multifactor gene-environment interactions and ovarian cancer risk: SNPs, obesity, and hormone-related risk factors
Goode, Ellen L. , Schildkraut, Joellen M. , Usset, Joseph , Fridley, Brooke L. , Pharoah, Paul D.P.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4684-4684

10.1158/1538-7445.am2015-4684 Get It

Abstract Background: We investigated the role of multifactor interactions and epithelial ovarian cancer (EOC) risk using data collected within the Collaborative Oncological Gene-environment Study and the Ovarian Cancer Association Consortium containing 18,000 EOC cases and 26,000 controls. To date, researchers have identified 18 EOC susceptibility loci. However, it has been estimated that many more common variant loci exist; we hypothesized that some of the unexplained variation is due to gene-environment interactions. Similar to breast and endometrial cancers, many EOC risk factors relate to estrogen exposure, and increased levels of estrogen has been associated with obesity in post-menopausal women. Therefore, we hypothesized that gene-environment interactions dealing with hormone-related risk factors could differ between obese and non-obese women. Methods: We considered multifactor interactions between single nucleotide polymorphisms (SNPs) and six hormone-related factors: oral contraceptive use; parity; endometriosis; tubal ligation; hormone replacement therapy (HRT); and estrogen use; and assessed whether these GE interactions differed between obese and non-obese women. The SNPs included in this analysis included the top associated markers within the 18 confirmed risk loci, as well as, 36,811 SNPs that lie within 84 candidate gene regions related to hormone biosynthesis & metabolism and insulin-like growth factors. For the candidate SNP analyses, we assessed multifactor interactions across environmental factors using logistic regression models including age, study site, and population substructure. For the candidate gene analyses, a two-stage screening and testing procedure was utilized. All analyses were completed including: (1) all histologies; and (2) only serous histology. Results: For the 18 known EOC risk loci, no hormone-related risk factors showed statistically significant interaction at a threshold of 10-4. In contrast, the two-stage analysis of the candidate genes found several significant gene-environment-environment effects, after adjusting for multiple testing. For analysis of all cases, the SNPs in the following candidate genes showed a multifactor interaction with a hormone-related risk factor and obesity: IGFBP5 (HRT, rs729597, p = 1.3×10-13), CGA (HRT, rs58124219, p = 1.0×10-5), and SSTR1 (parity, rs77266093, p = 1.1×10-5). Similarly, the serous histology analyses detected a multifactor interaction with HRT, obesity and IGFBP5 (rs729597, p = 8.8×10-5). Additionally, serous only analyses also detected an interaction involving ESR1 (tubal ligation, Chr6:152246911(indel), p = 8.0×10-6). Conclusions: In a very large case-control collection, assessment of multifactor gene-environment interaction is feasible, and, here, suggest that the relationship between SNPs in candidate genes and hormone-related risk factors in EOC susceptibility may vary. Citation Format: Joseph Usset, Brooke Fridley, Ellen Goode, Joellen Schildkraut, Paul Pharoah. Assessment of multifactor gene-environment interactions and ovarian cancer risk: SNPs, obesity, and hormone-related risk factors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4684. doi:10.1158/1538-7445.AM2015-4684
Abstract 4682: Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease
Palakal, Maya, Hartmann, Lynn C. , Frost, Marlene H., Brinton, Louise A. , Papathomas, Daphne, Visscher, Daniel W., Figueroa, Jonine D. , Pfeiffer, Ruth M. , Degnim, Amy C. , Radisky, Derek C. , Stallings‐Mann, Melody , Sherman, Mark E.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4682-4682

10.1158/1538-7445.am2015-4682 Get It

Abstract Purpose: Breast biopsies with benign findings (benign breast disease [BBD]) outnumber biopsies revealing in-situ or invasive cancer 4:1, providing an opportunity to identify histopathological features that predict breast cancer risk. Greater degrees of involution of terminal duct lobular units (TDLUs), the structures within the breast that produce milk and the primary source of breast cancer precursors, have been inversely associated with breast cancer risk among women with BBD. We recently developed measures to quantitate levels of TDLU involution, which demonstrate high inter/intra pathologist reproducibility. Here we assessed whether TDLU counts/100mm2 and median TDLU span (microns), two measures inversely related to degree of TDLU involution, are associated with subsequent breast cancer risk among women with BBD. Methods: From the Mayo BBD cohort (n = 9,376), we evaluated benign biopsies from 99 women who later developed breast cancer (cases) and 145 age-matched controls who did not develop breast cancer. Digitized images of biopsy sections were reviewed to enumerate TDLUs/mm2 and measure median TDLU span (microns) for up to ten normal TDLUs. Breast cancer risk factors were available from questionnaires or medical records. To assess associations with breast cancer risk, subjects were categorized into quartile levels of TDLU counts and median TDLU spans, based on data from controls. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models, adjusted for histologic type of BBD, family history of breast cancer and menopausal hormone use. Results: Compared to controls, women who developed breast cancer had higher median number of TDLU counts/100mm2 (28 vs 20, p = 0.03) and larger TDLU spans (300 vs 267 microns, p = 0.14). In multivariable models higher TDLU counts (quartile4 vs. quartile1, OR = 2.44, 95%CI = 0.96-6.19, ptrend = 0.02) and larger TDLU span measures (quartile4 vs. quartile1, OR = 2.83, 95%CI = 1.13-7.06, ptrend = 0.03) were associated with subsequent diagnosis of breast cancer. Combinatorial metrics of TDLU counts with median TDLU span measures identified women at higher risk; specifically, women above the median for both TDLU span and TDLU counts had an OR = 3.75 (95%CI = 1.40-10.00, ptrend = 0.008), compared with women below the median for TDLU span and TDLU counts. Conclusion: These data show that lack of TDLU involution, as measured by increased persistence of TDLU counts, larger median TDLU spans and cross-classification using these measures was associated with increased breast cancer risk among women with BBD, extending prior work in this cohort based on other TDLU involution metrics. Future studies to identify determinants of TDLU involution, its association with breast cancer risk and its potential as an intermediate endpoint in prevention studies warrant consideration. Citation Format: Jonine D. Figueroa, Ruth Pfeiffer, Maya Palakal, Amy C. Degnim, Derek Radisky, Lynn C. Hartmann, Marlene Frost, Melody L. Stallings Mann, Louise A. Brinton, Daphne Papathomas, Daniel Visscher, Mark E. Sherman. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4682. doi:10.1158/1538-7445.AM2015-4682
Abstract 4662: Framework for clinical evaluation of chemopreventive agents: Defining criteria for future assessment
Alberts, David S., Walsh, Naomi , Brown, Powel H. , Limburg, Paul J. , Sherman, Mark E. , Szabó, Éva

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4662-4662

10.1158/1538-7445.am2015-4662 Get It

Abstract Background Although a number of cancer chemopreventive agents have now been evaluated in phase II and phase III clinical trials that assess their efficacy and tolerability in both high risk and general populations, few have shown clear efficacy and uptake of approved agents has been disappointingly low. Therefore, chemopreventive agents should undergo rigorous screening prior to clinical trial evaluation in order to improve the selection of suitable agents for testing in large, expensive multi-center phase III trials. The aim of this study is to develop a descriptive method for prioritizing candidate agents for further development. Methods This framework was developed through a systematic literature review of Pubmed/Medline, Embase and The Cochrane Library. A semi-quantitative assessment focusing on efficacy and toxicity/tolerability was established based on expert input. Data from clinical trials, cancer epidemiological, observational and preclinical studies, including in vivo and in vitro basic research, was used to retrospectively evaluate the clinical application and effectiveness of cancer chemopreventive agents. Two chemopreventive agents with either a positive (aromatase inhibitors (AIs) for breast cancer) or negative (selenium for lung cancer) phase III clinical trial outcome were subsequently evaluated to determine the usefulness of the framework. Results Chemopreventive agents must reduce or reverse the process of carcinogenesis in normal or pre-malignant tissue with minimal toxicity. Evaluation of efficacy included data from preclinical and animal models, epidemiological studies, and clinical trials (both early phase trials in the organ of interest as well as secondary endpoints from other relevant studies). Agent suitability evaluation included assessment of toxicities, tolerability, and agent specific attributes (PK/PD, bioavailability, dosing, etc.). Examination of selenium and AI historical data in these categories revealed strong concordance with phase III outcomes. The detailed descriptive evaluation of the agents will be presented. Conclusion This framework provides a descriptive paradigm for cancer chemopreventive agent evaluation through systematic and rigorous interrogation. Thorough, standardized evaluation of all available preclinical, epidemiological, and clinical data should be strongly encouraged to better inform the investments required for clinical trials. Citation Format: Naomi Walsh, David S. Alberts, Powel Brown, Paul Limburg, Mark Sherman, Eva Szabo. Framework for clinical evaluation of chemopreventive agents: Defining criteria for future assessment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4662. doi:10.1158/1538-7445.AM2015-4662
Abstract 4635: Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility
Permuth‐Wey, Jennifer, Reid, Brett M. , Chen, Zhihua , Gayther, Simon A. , Goode, Ellen L. , Iversen, Edwin S. , Pearce, Leigh, Phelan, Catherine, Rossing, Mary Anne, Schildkraut, Joellen M. , Sellers, Thomas A. , Chen, Y. Ann , Lin, Hui‐Yi , Monteiro, Álvaro N.A. , Berchuck, Andrew , Chenevix‐Trench, Georgia , Doherty, Jennifer A. , Pharoah, Paul D.P. , Ramus, Susan J. , Rossing, Mary Anne

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4635-4635

10.1158/1538-7445.am2015-4635 Get It

Abstract Background: Recent bioinformatic analyses and high-throughput sequencing efforts have revealed that RNA editing is a widespread post-transcriptional modification that affects non-coding repetitive elements throughout the genome. This modification, which involves the conversion of adenosine into inosine, is mediated by the action of the adenosine deaminases acting on RNA (ADAR) family of enzymes. Based on reports of dysfunctional ADAR expression in epithelial ovarian cancers (EOC), we hypothesized that single nucleotide polymorphisms (SNPs) in five ADAR genes (ADAD1, ADAR1, ADAR2, ADAR3, SND1) may contribute to EOC susceptibility, potentially by altering the expression of corresponding genes in ovarian tissues. Methods: Using directly genotyped and imputed data from 10,891 invasive EOC cases and 21,693 healthy controls of European ancestry represented in the international Collaborative Oncological Gene-environment Study, we evaluated the frequency of 7,133 SNPs in 5 RNA editing genes. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) between genotypes and case status under a log-additive genetic model, with adjustment for the first five principal components representing European ancestry. Subgroup analysis was conducted for the four main histologic sub-types of EOC. We also aggregated SNP-level data and conducted gene-level analyses using the Admixture Maximum Likelihood (AML) test and the Sequence-Kernel Association test for the combined effect of common and rare variants (SKAT-CR). Results: Association analysis revealed a top risk-associated SNP (OR (95% CI) = 1.39 (1.17-1.64)) in ADAR3 with P = 1.3 x10−4, 17 additional SNPs in ADAR1, ADAR3, or SND1 with P = 10−4, and 51 SNPs with P = 10−3; this observed number of statistically-significant SNPs was greater than expected. When restricting to the 6,500 invasive serous adenocarcinomas, the magnitude of association strengthened for numerous SNPs. Exploratory analysis for the less common histologic subtypes (endometrioid (n = 1,439), mucinous (n = 696), and clear cell (n = 660)) revealed SNP-level associations (P<10−3) unique to each sub-type. Gene-level analyses based on AML and SKAT-CR revealed that ADAR1 was globally associated (P<0.10) with susceptibility to invasive EOC, with P = 0.024 and P = 0.023, respectively. Expression quantitative trait locus analysis is underway to evaluate associations between genotype and gene expression in EOC and precursor tissues using data from The Cancer Genome Atlas Project and other sources. Conclusions: Preliminary data from this large-scale collaboration suggest that germline variation involving RNA editing genes may influence susceptibility to EOC. This novel finding warrants further investigation, as inherited and acquired alterations affecting RNA editing may serve as important biological mechanisms that promote the development of EOC and possibly other malignancies. Citation Format: Jennifer Permuth-Wey, Brett M. Reid, Y. Ann Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, Georgia Chenevix-Trench, Jennifer Doherty, Simon Gayther, Ellen Goode, Edwin Iversen, Leigh Pearce, Paul D. P. Pharoah, Catherine Phelan, Susan Ramus, Mary Anne Rossing, Joellen Schildkraut, Thomas Sellers, on behalf of the Ovarian Cancer Association Consortium. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4635. doi:10.1158/1538-7445.AM2015-4635
Abstract 4634: Variants within super-enhancer regulatory elements associate with epithelial ovarian cancer risk
Reid, Brett M. , Permuth‐Wey, Jennifer, Chen, Zhihua , Gayther, Simon A. , Goode, Ellen L. , Iversen, Edwin S. , Pearce, Leigh, Phelan, Catherine, Rossing, Mary Anne, Schildkraut, Joellen M. , Sellers, Thomas A. , Chen, Y. Ann , Lin, Hui‐Yi , Monteiro, Álvaro N.A. , Berchuck, Andrew , Chenevix‐Trench, Georgia , Doherty, Jennifer A. , Pharoah, Paul D.P. , Ramus, Susan J.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4634-4634

10.1158/1538-7445.am2015-4634 Get It

Abstract Background: Cell-type-specific super enhancers, or large clusters of mediator-rich enhancers, are highly transcribed regions of the genome with key functions in the maintenance of cell identity and control. These regulatory elements are easily perturbed and enriched for disease-associated sequence variation. Identification of disease-associated super-enhancers and investigation of their sequence variants may help identify important, biologically relevant associations previously overlooked by genome-wide studies. Thus, we sought to identify variants within ovarian tissue specific super-enhancers and investigate their association with epithelial ovarian cancer (EOC) susceptibility. Methods: We utilized genotype data from a European population of ∼11,000 invasive EOC cases and 22,000 healthy controls from the Ovarian Cancer Association Consortium. A public catalog of 478 super-enhancers, identified by peak histone H3K27ac ChIP-seq signal in ovarian tissue, was used to identify 72,116 variants located within 344 super-enhancer regions. Unconditional logistic regression (log-additive model) was used to assess individual SNP-EOC risk associations. Additionally, we reviewed associations within 500 kb of super-enhancer regions to identify proximal associated variants. When LD structure indicated, we employed conditional analysis to determine independence of the super-enhancer signal. Gene-EOC risk associations were assessed with the Admixture Maximum Likelihood (AML) test and Sequence-Kernel Association Test (SKAT) for the combined effect of common and rare (MAF<0.01) variants. Models were adjusted for population stratification using the first five principal components. To adjust for multiple comparisons, a false discovery rate of 10% was used. Results: The most significant SNP observed was rs147487657 (p = 7.7×10−6) on locus 2q37.3 in the HDAC4 gene and there were an additional 12 SNPs with p<1.0×10−4, although not significant at 10% FDR. Gene-level analyses identified two super-enhancers significantly associated with EOC risk. An enhancer at the previously reported 2q31 locus, containing HOXD8 and HOXD-AS2, associated (SKAT p = 4.3×10−5; AML p<0.001) with the top SNP located within the 5′UTR of HOXD8 transcription factor (rs847163 (T>C); p<2.08×10−5). Conditional analysis did not identify an independent association within the super-enhancer region. The second EOC-associated super-enhancer identified was at locus 1q32 (SKAT p = 0.00052, AML p = 0.001) containing the CSRP1 gene. There were 6 SNPs with p<0.001 and 16 SNPs with p<0.01, all were inversely associated with risk and consistent with the top hit at rs927901 T>C (OR = 0.94; 95% CI: 0.90-0.97; p = 2.1×10−4). Associations varied by histologic subtype, possibly due to variance in disease relevant super-enhancer cell-type.Conclusion: These findings suggest germline variation within super-enhancer regions may contribute to EOC susceptibility Citation Format: Brett M. Reid, Jennifer Permuth-Wey, Y. Ann Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, Georgia Chenevix-Trench, Jennifer Doherty, Simon Gayther, Ellen L. Goode, Edwin Iversen, Leigh Pearce, Paul Pharoah, Catherine Phelan, Susan Ramus, Mary Anne Rossing, Joellen Schildkraut, Thomas Sellers, on behalf of the Ovarian Cancer Association Consortium. Variants within super-enhancer regulatory elements associate with epithelial ovarian cancer risk. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4634. doi:10.1158/1538-7445.AM2015-4634
Abstract 4633: Evidence that long non-coding RNA variants associate with epithelial ovarian cancer risk
Sellers, Thomas A. , Reid, Brett M. , Richards, Edward J., Teer, Jamie K. , Chen, Zhihua , Goode, Ellen L. , Iverson, Edwin S., Pearce, Leigh, Phelan, Catherine, Rossing, Mary Anne, Schildkraut, Joellen M. , Cheng, Jin Q. , Gayther, Simon A. , Permuth‐Wey, Jennifer, Chen, Y. Ann , Lin, Hui‐Yi , Monteiro, Álvaro N.A. , Berchuck, Andrew , Chenevix‐Trench, Georgia , Doherty, Jennifer A. , Pharoah, Paul D.P. , Ramus, Susan J.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4633-4633

10.1158/1538-7445.am2015-4633 Get It

Abstract Background: Genome wide association studies (GWAS) have identified 20 loci associated with epithelial ovarian cancer (EOC) risk. Additional EOC risk loci await identification, and biological approaches may represent a useful strategy for overcoming sample size limitations. The ENCODE project recently concluded that only ∼1.2% of the genome encodes proteins, but at least 20% exhibits biological function and over 80% exhibits biochemical indices of function. Post-GWAS follow-up studies have firmly established that some associations are due to inter-individual differences in non-coding RNAs (ncRNAs). To estimate the magnitude of impact of variants in long non-coding RNAs (lncRNAs), we assessed enrichment of EOC-associated SNPs in lncRNA regions by comparing the density of EOC-associated loci between lncRNA regions, non-lncRNA regions, and the whole genome. Methods: The study population included ∼18,000 invasive EOC cases and 34,000 healthy controls of European ancestry from the Ovarian Cancer Association Consortium with GWAS data imputed to 1000 Genomes Project (1KGP) density. Density was compared with two measures: average chromosome length required for one EOC-associated SNP (kb/locus) and average number of tested SNPs containing one EOC-associated SNP (SNPs/locus). Coordinates and annotation for 13,870 lncRNA genes were downloaded from the publicly available GENCODE (v19) database and were used to annotate SNPs from the 1KGP imputed GWAS data, yielding 13,192 lncRNA genes with biallelic variants imputed at rsquare ≥0.25. A SNP was considered EOC-associated if it reached a significance level of P<10−5. Results: Genome-wide, 11.6% of the 15,123,646 tested SNPs fell within lncRNA regions. Of 5,294 EOC-associated SNPs that were identified, 27.7% were located within lncRNAs, a higher frequency than expected (<v:shape style = “WIDTH: 16.5pt; HEIGHT: 18pt” id = _x0000_i1026 equationxml = ‘14pχ2′ type = “#_x0000_t75”> = 9.35×10−22). Additionally, EOC-associated SNPs were located on average every 237.6 kb (or 1204 tested SNPs) in lncRNA regions versus every 657.7 kb (or 3489 SNPS) in non-lncRNA regions and every 541.5 kb (or 2857 SNPs) in the whole genome, clearly demonstrating an enrichment of EOC-associated loci in lncRNA regions. A total of 1,464 lncRNA SNPs from 53 unique lncRNAs associated with EOC risk (P<10−5); 70 of the identified lncRNA SNPs had P-values between 10−20 and 10−32, and 221 had P-values between 10−10 and 10−15, representing 21 unique regions > 500kb apart. Conclusions: These results justify efforts to integrate functional and population level genetic data on lncRNA regions to explore a new paradigm that addresses the problem of the missing heritability for cancer where restrictions in sample size and statistical power limit the ability to discover additional risk loci. Citation Format: Thomas A. Sellers, Brett M. Reid, Y. Ann Chen, Hui-Yi Lin, Edward Richards, Jamie Teer, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, Georgia Chenevix-Trench, Jennifer Doherty, Ellen Goode, Edwin Iverson, Leigh Pearce, Paul Pharoah, Catherine Phelan, Susan Ramus, Mary Anne Rossing, Joellen Schildkraut, Jin Cheng, Simon Gayther, Jennifer Permuth-Wey, on behalf of the Ovarian Cancer Association Consortium. Evidence that long non-coding RNA variants associate with epithelial ovarian cancer risk. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4633. doi:10.1158/1538-7445.AM2015-4633
Abstract 4629: Multiple myeloma susceptibility loci examined in African and European ancestry populations
Rand, Kristin A. , Song, Chi , Déan, Eric, Serie, Daniel, Curtin, Karen , Hazelett, Dennis J. , Hwang, Amie E. , Sheng, Xin , Stram, Alex , Huff, Carol Ann , Bernal‐Mizrachi, Leon , Roos, Anneclaire De, Pawlish, Karen , Peters, Edward , Bock, Catherine, Conti, David V. , Zimmerman, Todd M., Huntsman, Scott , Graff, John, Mehta, Jayesh, Janakiraman, Nalini, Severson, Richard K., Brown, Elizabeth E. , Kolonel, Laurence N. , Henderson, Brian E., Spinelli, John J., Zonder, Jeffrey A. , Camp, Nicola J. , Vachon, Celine M. , Stram, D. O., Haiman, Christopher A. , Berg, David Van Den , Tomasson, Michael H. , Ailawadhi, Sikander , Singhal, Seema , Colditz, Graham A. , Chanock, Stephen Jacob , Lieber, Michael R. , Klein, Eric A. , Brooks‐Wilson, Angela , Rajkumar, S. Vincent , Slager, Susan L. , Giles, Graham G. , Chiu, Brian C.‐H. , Anderson, Kenneth C. , Orlowski, Robert Z. , Lonial, Sagar , Vachon, Celine M. , Ziv, Elad , Cozen, Wendy , Hazelett, Dennis J , Conti, David V

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4629-4629

10.1158/1538-7445.am2015-4629 Get It

Abstract Genome-wide association studies (GWAS) of multiple myeloma (MM) in Northern Europeans have identified seven novel risk loci (2p23.3, 3p22.1, 3q26.2, 6p21.33, 7p15.3, 17p11.2, 22q13.1). We performed a multiethnic meta-analysis of these regions in 1,274 MM patients and 1,486 controls of European ancestry (EA) and 1,049 MM patients and 7,080 controls of African ancestry (AA), leveraging the differential linkage-disequilibrium of these populations in order to better localize the putative functional variants. We observed directionally consistent effects for all seven index SNPs in both populations, with four significantly associated (p<0.05) with risk in EAs (3p22.1, 7p15.3, 17p11.2, 22q13.1), and two significantly associated with risk in AAs (7p15.3 and 22q13.1). In a fixed effects meta-analysis of six regions (excluding the HLA region on chromosome 6), variation in five of the regions (2p33.3, 3p22.1, 7p15.3, 17p11.2, 22q13.1) had statistically significant associations with risk (Table 1). In one region, the index variant had the strongest association [rs4487645 at 7p15.3, (OR = 1.30, p = 8.7×10−8)]. Five of the six most significantly associated variants identified in the multiethnic analyses overlapped with biologically relevant features indicating regulatory activity based on CD20+ (B lymphocyte) cells, showing evidence of potential function; those included a missense variant in (17p11.2, rs34562254, Pro251Leu) in TNFRSF13B, which encodes a lymphocyte-specific protein in the tumor necrosis factor receptor family that interacts with the NF-kb pathway. Our study shows that these regions are important in MM risk across ethnicities and further supports the use of multiple ethnic groups in genetic studies to enhance identification of risk variants. Table 1.Most significant associations for each region in the multiethnic meta-analysis.Individuals of European AncestryIndividuals of African AncestryMulitethnic Metar2 with IndexcCHRSNPRAaFreqbORP-valueFreqbORP-valueORP-valueP-het2rs732075G0.591.222.0×10−30.621.122.0×10−21.162.6×10−40.280.09/0.283rs73069394A0.191.243.0×10−30.621.181.5×10−21.201.3×10−50.550.77/0.963rs12637184G0.761.136.0×10−20.921.192.7×10−11.151.0×10−20.640.94/1.007rs4487645C0.671.237.0×10−40.891.485.5×10−51.308.7×10−80.07-d17rs34562254A0.121.452.4×10−50.131.212.2×10−31.312.5×10−60.120.33/0.9022rs139400T0.491.224.0×10−40.531.172.1×10−31.191.2×10−60.630.63/0.96aRisk allelebFrequency of the risk allele in European and African ancestry studiescr2 metrics based on 1000 Genomes Project AFR/EUR populationsdIndex SNP Citation Format: Kristin A. Rand, Chi Song, Eric Dean, Daniel Serie, Karen Curtin, Dennis Hazelett, Amie E. Hwang, Xin Sheng, Alex Stram, David J. Van Den Berg, Carol Ann Huff, Leon Bernal-Mizrachi, Michael H. Tomasson, Sikander Ailawadhi, Anneclaire De Roos, Seema Singhal, Karen Pawlish, Edward Peters, Catherine Bock, David V. Conti, Graham Colditz, Todd Zimmerman, Scott Huntsman, John Graff, African Ancestry Prostate Cancer GWAS Consortium,African Ancestry Breast Cancer GWAS Consortium, Stephen J. Chanock, Michael Lieber, Jayesh Mehta, Eric A. Klein, Nalini Janakiraman, Richard K. Severson, Angela R. Brooks-Wilson, Vincent Rajkumar, Elizabeth E. Brown, Laurence Kolonel, Susan Slager, Brian E. Henderson, Graham G. Giles, John J. Spinelli, Brian Chiu, Kenneth C. Anderson, Jeffrey Zonder, Robert Z. Orlowski, Sagar Lonial, Nicola Camp, Celine Vachon, Elad Ziv, Dan O. Stram, Christopher A. Haiman, Wendy Cozen. Multiple myeloma susceptibility loci examined in African and European ancestry populations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4629. doi:10.1158/1538-7445.AM2015-4629
Abstract 4626: Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations
Rothman, Nathaniel , Bassig, Bryan A. , Au, Wing‐Yan, Sangrajrang, Suleeporn , Tse, Jovic, Berndt, Sonja I. , Zheng, Tongzhang, Zhang, Heping , Pornsopone, Pattarapong, Lee, Je‐Jung , Kim, Hyeoung‐Joon , Skibola, Christine F., Burdette, Laurie , Brennan, Paul , Liang, Raymond , Chanock, Stephen, Lan, Qing , Rothman, Nathaniel , Cerhan, James R. , Kim, Hee Nam , Hu, Wei, Vijai, Joseph , Yeager, Meredith , Shin, Min‐Ho

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4626-4626

10.1158/1538-7445.am2015-4626 Get It

Abstract Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) and is the most common NHL subtype diagnosed worldwide. Some epidemiologic data have indicated differences in DLBCL incidence rates and subtype distributions between Eastern Asian and Western countries. The first large-scale genome-wide association study (GWAS) of DLBCL with over 4000 cases conducted among individuals of European ancestry recently identified five independent SNPs that achieved genome-wide significance, and two SNPs that showed a suggestive association with DLBCL risk. In order to evaluate whether Eastern Asians and individuals of European ancestry share similar genetic risk factors for this disease, we attempted to replicate these GWAS findings in a pooled series of 1124 DLBCL cases and 3596 controls from Hong Kong, South Korea, and Thailand. Three of the five genome-wide significant SNPs from the DLBCL GWAS were significantly associated with DLBCL in our study population, including the top finding from the GWAS, EXOC2 rs116446171, which achieved genome-wide significance in our data (per allele OR = 2.04, 95% CI = 1.63-2.56; ptrend = 3.9 × 10-10). Additionally, we observed a significant association with PVT1 rs13255292 (per allele OR = 1.34, 95% CI = 1.19-1.52; ptrend = 2.1 × 10-6), which was the second strongest finding in the GWAS, and with HLA-B rs2523607 (per allele OR = 3.05, 95% CI = 1.32-7.05; ptrend = 0.009). Our study, which provides the first evaluation in Eastern Asians of SNPs definitively associated with DLBCL risk in individuals of European ancestry, indicates that at least some of the genetic factors associated with risk of DLBCL are similar between these populations. Citation Format: Nathaniel Rothman, Bryan A. Bassig, James R. Cerhan, Wing-Yan Au, Hee Nam Kim, Suleeporn Sangrajrang, Wei Hu, Jovic Tse, Sonja Berndt, Tongzhang Zheng, Heping Zhang, Pattarapong Pornsopone, Je-Jung Lee, Hyeoung-Joon Kim, Christine F. Skibola, Joseph Vijai, Laurie Burdette, Meredith Yeager, Paul Brennan, Min-Ho Shin, Raymond Liang, Stephen Chanock, Qing Lan. Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4626. doi:10.1158/1538-7445.AM2015-4626
Abstract 4624: Clinical impact of telomere shortening in normal and leukemia cells in chronic lymphocytic leukemia
Beiggi, Sara, Zhang, Yunli , Schmidt, Robert A. , Johnston, James B. , Yang, Lin , Schmidt, Robert, Gibson, Spencer B.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4624-4624

10.1158/1538-7445.am2015-4624 Get It

Abstract Introduction: Prognosis in CLL is heterogeneous with the elderly, males and those with multiple co-morbidities having the highest risk of poorer outcomes. Whether this reflects differences in the biology of CLL or the result of altered immunosuppression is unknown. In normal individuals, the telomeres in somatic cells shorten with age, predisposing those with shorter telomeres to death from infections, cancer and cardiovascular disease. In chronic lymphocytic leukemia (CLL), short telomere length in the leukemia cells predicts poor prognosis. The contribution of un-modifiable factors of age, sex or comorbidities to telomere shortening in CLL has not been elucidated. In the present study, we evaluated buccal cell (BC) telomere length in patients with CLL, to determine if this is predictive of survival, and can enhance the predictive value of leukemia cell telomere length. Methods: The Manitoba CLL tumor bank contains 168 samples from newly diagnosed CLL patients between 2007-2011; with a median follow-up of 4 years. Half of these patients required chemotherapy and one-tenth have died. Genomic DNA was extracted from purified CLL cells and buccal cells (BC) collected at diagnosis. Telomere length was established by multiplex quantitative real-time PCR. Telomere/standard (t/s) ratio was calculated using the beta-globulin gene as the standard. Statistical analysis was performed using Statistical Analysis Software (SAS) and Prism software. Results: The median adjusted telomere length was shorter in CLL cells than in BCs being 0.53 and 2.01, respectively. In BCs, telomere length significantly shortened with increasing age (p = 0.01) but was not reflective of the number of comorbidities or survival. In contrast, telomere length in CLL cells was independent of age (p = 0.44) and sex (p = 0.75). Short CLL telomere length correlated with other biological and clinical markers of poorer prognosis including un-mutated IGHV status (p<0.0001), Zap70 positivity (p = 0.05), CD38 positivity (p = 0.003), short lymphocyte doubling time (p = 0.004), higher Rai stage (p = 0.02) and an earlier time to treatment (p<0.0001). Patients with short CLL telomeres had also decreased survival at four years (p = 0.05); living 22 months less than those with normal telomeres. Adjusting for BC telomere length improved the prognostic value of CLL telomere length as an independent predictor of survival. Conclusions: These results demonstrate that BC telomere length in CLL patients shorten with age independent of co-morbidities, secondary malignancies and the respective CLL telomere length. CLL telomere shortening is strongly associated with biochemical and clinical markers of disease progression and survival. The predictive value for overall survival is enhanced by correcting for changes in buccal cell telomere length. Note: This abstract was not presented at the meeting. Citation Format: Lin Yang, Sara Beiggi, Yunli Zhang, Robert Schmidt, Spencer B. Gibson, James B. Johnston. Clinical impact of telomere shortening in normal and leukemia cells in chronic lymphocytic leukemia. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4624. doi:10.1158/1538-7445.AM2015-4624